Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 12 of 14, showing 5 Applications out of 68 total, starting on record 56, ending on 60

# Protocol No Study Title Investigator(s) & Site(s)

56.

ECCT/17/05/03   TDF IVR-002 Study
    Phase 1 Safety and Pharmacokinetic Study of a Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring in Sexually Active Women (TDF IVR-002)   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
Partners in Health Research & Development (Thika Partners Clinical Trial Site)
 
View

57.

ECCT/17/05/01   Multicenter Study of the Accuracy of the BD MAXâ„¢MDR-TB Assay
    Multicenter Study of the Accuracy of the BD MAX™MDR-TB Assay for Detection of M. tuberculosis Complex and Mutations Associated with Resistance to Rifampin or Isoniazid   
Principal Investigator(s)
1. SAMUEL GURRION OUMA
Site(s) in Kenya
KENYA MEDICAL RESEARCH INSTITIUTE
 
View

58.

ECCT/17/09/03   A5354
    Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses   
Principal Investigator(s)
1. Deborah Langat
Site(s) in Kenya
Kenya Medical Research Institute Walter Reed Project Clinical Research Centre
 
View

59.

ECCT/21/12/02   The WHO ACTION Trial
    ACTION III: A multi-country, multi-centre, three-arm, parallel group, double-blind, placebo-controlled, randomized trial of two doses of antenatal corticosteroids for women with a high probability of birth in the late preterm period in hospitals in low-resource countries to improve newborn outcomes   
Principal Investigator(s)
1. Frederick Namenya Were
2. John Kinuthia
3. Zahida Parveen Qureshi
Site(s) in Kenya
1. Coast General Teaching and Referral Hospital (Mombasa county)
2. Thika Level 5 Hospital (Kiambu county)
3. Nakuru Level 5 Hospital (Nakuru county)
 
View

60.

ECCT/19/03/02   PREVENT TD
    A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg daily or 550 mg twice daily) for Chemoprophylaxis Against Travellers’ Diarrhoea (TD) Among Active Duty Deployed U.S. and British Military Personnel (PREVENT TD)   
Principal Investigator(s)
1. Flynn Alexander
Site(s) in Kenya
Nyati Barracks, British Army Training Unit, Kenya
 
View